跳至主要内容
临床试验/NCT00574756
NCT00574756终止不适用

The Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

University of California, San Diego1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
14
试验地点
1
主要终点
Change in E/Ea

研究概览

简要总结

The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate of severe diastolic dysfunction, E/Ea>12
  • Preserved systolic function
  • NYHA Class I-II

排除标准

  • QTc >450 msec at enrollment
  • Taking medications that prolong QT interval or are potent inhibitors of CYP3A
  • Significant coronary artery disease
  • Severe valvular disease
  • Hepatic disease
  • Severe kidney disease
  • Women of childbearing age
  • Prior serious ventricular arrhythmia

研究组 & 干预措施

1

Other

Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks

干预措施: ranolazine (Drug)

2

Other

Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks

干预措施: ranolazine (Drug)

结局指标

主要结局

Change in E/Ea

时间窗: 2 weeks

次要结局

  • changes in mitral inflow parameters (E, A, IVRT, DT)(2 weeks)
  • Changes in pulmonary venous inflow (S, D, a reversal)(2 weeks)
  • Changes in tissue doppler parameters (Ea, Aa)(2 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Effect of Ranolazine on Echocardiographic Indices of... | 临床试验